ArticleInfection and drug resistance2019
Multilocus sequence typing and
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Prevalence and Genomic Characterization of ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Genomic Characterization, Antimicrobial Resistance Profiles, andAnimals : an open access journal from MDPI · 2026Article
- Antimicrobial resistantOne health (Amsterdam, Netherlands) · 2026Review
- Whole-Genome Sequence Analysis of Colistin-Resistant,Antibiotics (Basel, Switzerland) · 2026Article
- Convergence of plasmid-driven virulence and antibiotic resistance in Escherichia coli.Nature communications · 2025Article
- Longitudinal study on the genetic diversity of extended-spectrum cephalosporin resistantFrontiers in microbiology · 2025Article
- Threats across boundaries: the spread of ESBL-positiveFrontiers in microbiology · 2025Review
- The Global Rise of ESBL-ProducingAnimals : an open access journal from MDPI · 2024Review
- Extended-spectrum beta-lactamase-producingMicrobiology spectrum · 2024Article
- Exploring Extended-Spectrum Beta-Lactamase (ESBL)-ProducingPathogens (Basel, Switzerland) · 2024Review
- Antibiotic-resistant characteristics and horizontal gene transfer ability analysis of extended-spectrum β-lactamase-producingFrontiers in veterinary science · 2024Article
- Non-replicative phage particles delivering CRISPR-Cas9 to target major blaCTX-M variants.PloS one · 2024Article
- Antimicrobial Resistance in Bacteria from Meat and Meat Products: A One Health Perspective.Microorganisms · 2023Review
- Epidemiological study of antimicrobial-resistant bacteria in healthy free-ranging bantengs (Veterinary world · 2023Article
- Detection of Extended-spectrum β-lactamase-producing Escherichia coli isolates by isothermal amplification and association of their virulence genes and phylogroups with extraintestinal infection.Scientific reports · 2023Article
- Characterization of anPathogens (Basel, Switzerland) · 2023Article
- Comparative meta-analysis of antimicrobial resistance from different food sources along with one health approach in Italy and Thailand.One health (Amsterdam, Netherlands) · 2023Article
- Longitudinal Study of Dynamic Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Pigs and Humans Living and/or Working on Pig Farms.Microbiology spectrum · 2023Article
- Article
- High Genetic Diversity and Antimicrobial Resistance inMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHere, we investigated the genetic relationships and characteristics of extended- spectrum beta-lactamase-producing PATIENTS AND
methodsFour hundred and nine rectal swabs were collected from healthy people and swine. A total of 212 ESBL-
resultsOverall,
conclusionProof of a direct transfer of ESBL-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.